Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA; Department of Immunology, Harvard Medical School, Boston, MA 02115, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA.
Immunity. 2024 Feb 13;57(2):223-244. doi: 10.1016/j.immuni.2024.01.013.
Immune responses must be tightly regulated to ensure both optimal protective immunity and tolerance. Costimulatory pathways within the B7:CD28 family provide essential signals for optimal T cell activation and clonal expansion. They provide crucial inhibitory signals that maintain immune homeostasis, control resolution of inflammation, regulate host defense, and promote tolerance to prevent autoimmunity. Tumors and chronic pathogens can exploit these pathways to evade eradication by the immune system. Advances in understanding B7:CD28 pathways have ushered in a new era of immunotherapy with effective drugs to treat cancer, autoimmune diseases, infectious diseases, and transplant rejection. Here, we discuss current understanding of the mechanisms underlying the coinhibitory functions of CTLA-4, PD-1, PD-L1:B7-1 and PD-L2:RGMb interactions and less studied B7 family members, including HHLA2, VISTA, BTNL2, and BTN3A1, as well as their overlapping and unique roles in regulating immune responses, and the therapeutic potential of these insights.
免疫应答必须受到严格调控,以确保最佳的保护免疫和耐受性。B7:CD28 家族内的共刺激途径为 T 细胞的最佳激活和克隆扩增提供了必要的信号。它们提供了关键的抑制信号,维持免疫稳态,控制炎症的解决,调节宿主防御,并促进耐受以防止自身免疫。肿瘤和慢性病原体可以利用这些途径逃避免疫系统的清除。对 B7:CD28 途径的理解的进步带来了免疫治疗的新时代,有有效的药物来治疗癌症、自身免疫性疾病、传染病和移植排斥。在这里,我们讨论了 CTLA-4、PD-1、PD-L1:B7-1 和 PD-L2:RGMb 相互作用以及研究较少的 B7 家族成员的共抑制功能的潜在机制,包括 HHLA2、VISTA、BTNL2 和 BTN3A1,以及它们在调节免疫应答中的重叠和独特作用,以及这些见解的治疗潜力。